Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis.

Abstract

Dupilumab is a biologic, acting on IL-4 and IL-13 pathways. Dupilumab has a pediatric indication for treating severe asthma and atopic dermatitis. We report a pediatric case concerning paucisymptomatic, transient, and self-resolving hyperthyroidism. The updated literature includes the case of an adult patient who reported with hyperthyroidism, which was transient and self-resolving. Despite that these cases were transient and self-resolving, we would suggest that thyroid function assessment could be included in the follow-up of patients treated with Dupilumab. Dupilumab discontinuation is not required pending endocrinological assessment, mainly if there is an optimal clinical response to the biologic.

• Authors: Maria Angela Tosca, Roberta Olcese, Donata Girosi, Emilio Casalini, Marco Scaglione, Giorgio Ciprandi
• Journal: Allergologia et immunopathologia (Allergol Immunopathol (Madr)) Vol. 51 Issue 3 Pg. 181-185 ( 2023) ISSN: 1578-1267 [Electronic] Singapore
• PMID: 37169576 (Publication Type: Case Reports)

Chemical References

• dupilumab
• Antibodies, Monoclonal
• Biological Products

Topics

• Adult
• Humans
• Adolescent
• Child
• Dermatitis, Atopic (drug therapy)
• Antibodies, Monoclonal (therapeutic use)
• Asthma (drug therapy)
• Hypersensitivity (drug therapy)
• Hyperthyroidism (drug therapy)
• Severity of Illness Index
• Biological Products (therapeutic use)
• Treatment Outcome